Skip to main content
Premium Trial:

Request an Annual Quote

Aclara, Amersham, PerkinElmer, Definiens, Syn X Pharma, Oxford GlycoSciences, Beckman Coulter, Ciphergen, Thermo Electron, Celera Genomics, Nonlinear Dynamics

Premium

Aclara Lays Off 30, Reports Small Revenues in Q1

Aclara BioSciences of Mountain View, Calif., laid off 30 employees last month, reducing its headcount to 65. The company reported revenues of $180,000 for the first quarter of 2003, down more than 50 percent from the same period last year, due to its discontinued microfluidics program. Losses amounted to $6.2 million, down from $9.1 million last year. As of March 31, the company had $101.3 million in cash resources. Aclara also said that it has expanded its eTag assay collaboration with Genentech, after it designed a customized eTag assay to measure specific receptor binding and signaling events.

 

Amersham Reports Growth in Proteomics

Amersham reported sales of £381 million ($612 million) for the first quarter, up six percent from last year. Within Amersham Biosicences, sales in discovery systems increased to £95 million ($153 million), “with growth in proteomics and bioassays compensating for the anticipated decline in genomics,” according to the company.

 

PerkinElmer Sees Revenues, Income Increase

PerkinElmer had $358.4 million in revenues during the first quarter of 2003, up from $346.3 million during the same period last year. It recorded a net income of $2.4 million for the quarter, compared to a net loss of $147.4 million last year. The company’s life sciences segment reported revenues of $103.9 million, down 11 percent from last year, especially due to lower instrument sales. At the end of the quarter, PE had $129.8 million in cash and cash equivalents.

 

Definiens Adds Distribution, Service Partners

Definiens of Munich has added a number of distributors and service partners for its software products. New distributors are AGB in Ireland and the UK, Greenmate in Korea, Immagini in Italy, ScienceMed in Singapore, ScienceServe in Central Europe, Textronica in Russia, and Tri-I in Taiwan; new service partners are TopLab and Wita in Germany.

 

Syn X Pharma Records Smaller Loss in Q1

In the first quarter of 2003, Syn X Pharma of Toronto had revenues totaling CA$3.5 million ($2.5 million), compared to CA$800,000 ($600,000) during the equivalent period last year. These resulted primarily from a milestone payment from Ortho-Clinical Diagnostics. Losses for the quarter totaled CA$300,000 ($210,000), compared with CA$2.1 million ($1.5 million) last year.

As of March 31, Syn X had cash resources totaling CA$2.5 million ($1.8 million).

 

OGS Reports Growing Losses for 2002

Oxford GlycoSciences reported preliminary unaudited results for the year 2002. The company had revenues of £14 million ($22.5 million), compared to £13.4 million ($21.5 million) the previous year. Losses amounted to £37.9 million ($60.9 million), compared to £25.3 million ($40.6 million) in 2001. At the end of 2002, the company had £136.4 million ($219 million) in cash, compared to £176.6 million ($283.7 million) the year before.

 

Beckman Coulter Increases Sales

Beckman Coulter increased its sales from $446.7 million in the first quarter of 2002 to $467.3 million this year. Its net earnings increased to $44.6 million from $28 million last year, much of this due to non-recurring items.

 

Ciphergen Boosts Revenues, Losses in Q1

Revenues for Ciphergen Biosystems of Fremont, Calif., increased to $12.8 million in the first quarter from $6.8 million the previous year. The company also recorded a higher net loss of $9.2 million for the quarter, compared to $7.2 million during the same period in 2002.

 

Thermo’s Revenues Grow

Thermo Electron reported first quarter revenues of $500.2 million, compared to $491.3 million during the same period last year. Its net income for the quarter was $36.4 million, compared to $115 million last year. First quarter revenues for the Life and Laboratory Sciences sector totaled $299 million, versus $281 million in 2002, partly because of strong sales of mass spectrometers.

 

Celera Sees Revenues Decline in Q1

Celera Genomics reported revenues of $20.3 million for the third quarter of fiscal year 2003, which ended March 31, down from $30.5 million last year. Its net loss narrowed to $26.7 million from $49.5 million last year. The company said it is now studying lung and colon cancer samples by proteomics and has selected for further validation 38 differentially expressed cell surface proteins identified in its pancreatic cancer study.

 

Nonlinear Adds Distributor in Canada

Nonlinear Dynamics of Newcastle upon Tyne, UK, has chosen United Bioinformatica of Calgary, Canada, as distributor for its image analysis and database software in Canada.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.